Early benefit assessment remains anchored at national level. Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG), the appropriate comparator therapy, patient-relevant endpoints, subgroups, evidence currency and tight procedural timelines remain decisive for whether European evidence can actually carry weight in the German procedure.
This is precisely where the Delta-Dossier becomes relevant. It describes the translation work between the European JCA dossier and the national AMNOG dossier: Which content can be usedWhere are references not sufficientAnd where do pharmaceutical companies need to address additional national requirements early on
This page explains what EU HTA means for Germany, how JCA and AMNOG interact, and why the Delta-Dossier is becoming the central interface between European evidence and German benefit assessment.
What does EU HTA mean for Germany
EU HTA creates a common European framework for the clinical assessment of health technologies. In the pharmaceutical sector, the focus is primarily on the Joint Clinical Assessment. Clinical data will be assessed jointly at European level so that Member States do not have to review the same evidence independently several times.
For Germany, this development is particularly relevant because AMNOG already provides an established procedure for early benefit assessment. The EU HTA Regulation therefore does not replace national assessment. Instead, it creates a new interface: European JCA results must be integrated into a national procedure that continues to follow its own assessment standards.
This particularly concerns the question of which populations, comparators, endpoints and subgroups are relevant for Germany. Even when a European JCA dossier is available, it remains necessary to assess whether the evidence it contains is sufficient for the German benefit assessment or whether additional national preparation is required.
For pharmaceutical companies, this creates a new planning task. EU HTA can reduce duplication if European and national requirements are considered together at an early stage. If this alignment does not succeed, parallel requirements emerge: a European JCA dossier on one side and a still demanding AMNOG dossier on the other.
Why JCA does not replace the AMNOG procedure
The Joint Clinical Assessment creates a common European basis for clinical assessment. It describes the submitted evidence, relevant effects and results in relation to the questions considered in the European procedure. However, it does not automatically result in a decision on the added benefit of a medicine in Germany.
The assessment of added benefit remains part of the national AMNOG procedure. The German assessment perspective, the appropriate comparator therapy, patient-relevant endpoints, methodological requirements and the requirements for the national dossier remain decisive. Pricing and reimbursement decisions also remain anchored at national level.
This creates an important distinction: the JCA can provide evidence that is referenced in the national procedure. But it does not automatically answer the German assessment question. What remains decisive is whether the European evidence fits the German question, particularly with regard to populations, comparator therapy, endpoints, subgroups and analysis methods.
For pharmaceutical companies, this means that a JCA dossier can be an important foundation, but it does not replace the strategic preparation of the AMNOG dossier. Companies that only address the national assessment after publication of the JCA report risk identifying too late where European and German requirements diverge.
Where EU HTA and AMNOG meet in practice
The key question is not whether JCA results will become relevant in the German AMNOG procedure. The key question is how they can be used there. European and German assessment processes do not automatically follow the same research question, the same comparator standard or the same methodological requirements.
The central transition point already lies in PICO scoping. At European level, population, intervention, comparator and outcomes are defined and consolidated for the JCA. For Germany, however, the decisive factor remains which question underlies the national benefit assessment. If the European PICO structure does not sufficiently reflect the German assessment perspective, additional translation work will be required later.
The appropriate comparator therapy is particularly relevant. While the JCA may bundle several European comparison questions, the German early benefit assessment is oriented towards the appropriate comparator therapy determined by the G-BA. If the evidence addressed in the JCA deviates from the comparator therapy relevant for Germany, a reference to the European dossier will not be sufficient.
Differences can also arise with endpoints, subgroups and analysis methods. Not every endpoint considered in the European procedure will automatically be suitable for the German benefit assessment. National requirements for analyses, evidence currency and dossier structure also remain relevant.
This means that the actual interface between EU HTA and AMNOG does not begin only when the national dossier is submitted. It begins earlier: with the question of whether European evidence is planned, structured and updated in such a way that it can be used robustly in the German procedure.
Why the Delta-Dossier becomes relevant
The Delta-Dossier becomes relevant where European JCA evidence cannot be transferred one-to-one into the German AMNOG procedure. It is not about formally repeating a European dossier. What matters is which content from the JCA dossier is robust for Germany, which evidence needs to be updated and where additional national requirements must be addressed.
The term Delta-Dossier is not an official regulatory term. In the German market access context, it describes the content and evidence required beyond the European JCA dossier in order to robustly address the requirements of the national AMNOG procedure.
In Germany, this translation work is particularly demanding. Early benefit assessment continues to follow its own assessment standards: the appropriate comparator therapy determined by the G-BA, nationally accepted patient-relevant endpoints, specific requirements for subgroups and analyses, and tight timelines for dossier submission.
A robust Delta-Dossier therefore connects two levels: it uses the European evidence from the JCA where it is applicable to Germany, and complements it where the national procedure requires additional preparation. Its value does not lie in the greatest possible number of references, but in the precise selection, interpretation and supplementation of evidence for the German benefit assessment.
PICO, appropriate comparator therapy, endpoints and timing: the critical interfaces
The greatest challenges arise where European evidence and German assessment requirements are not fully aligned. For the Delta-Dossier, four areas are therefore particularly decisive: PICO scoping, appropriate comparator therapy, endpoints and evidence currency.
PICO scoping determines early on which populations, interventions, comparators and endpoints are considered in the European JCA. For Germany, however, the decisive question is whether this structure sufficiently reflects the later AMNOG question. If relevant subgroups, comparison questions or endpoints are not appropriately covered, additional justification and supplementary evidence may be required in the national procedure.
The appropriate comparator therapy is the central reference point for assessing added benefit in the German procedure. A European JCA may include several comparators or different national perspectives. For the AMNOG dossier, however, the key question is whether the evidence is robust against the comparator therapy relevant for Germany.
National requirements also remain decisive for endpoints and analysis methods. Endpoints considered in European scoping are not automatically patient-relevant in the German procedure. National methodological requirements may also mean that analyses need to be supplemented, prepared differently or updated.
Timing is another critical factor. Literature searches, data cuts and newly available studies must be up to date at the start of the AMNOG procedure. As a result, the evidence base of the national dossier may differ from that of the JCA dossier. For the Delta-Dossier, it is therefore essential to plan early which evidence from the JCA can be used and where national updates will be required.
What pharmaceutical companies should prepare now
For pharmaceutical companies, it will be essential not to plan EU HTA and AMNOG as separate processes. The requirements of the European JCA and the German early benefit assessment need to be considered together at an early stage, ideally before or during PICO scoping, not only when the national dossier is being prepared.
As a first step, companies should assess which PICO constellations may actually become relevant for Germany. This includes the question of whether the populations, comparators and endpoints addressed in the European procedure sufficiently reflect the later German assessment perspective or whether alternative scenarios need to be prepared.
In parallel, the appropriate comparator therapy should be anticipated early. Even though the final national assessment takes place only in the AMNOG procedure, the expected comparator therapy already influences the question of which evidence in the JCA can be robust for Germany and where additional analyses or justifications may be required.
An early review of endpoints, subgroups and analysis methods is equally important. Companies should assess whether the European evidence meets German requirements for patient relevance, methodology and dossier structure. Where gaps are foreseeable, national preparation should not begin only after the JCA has been completed.
Finally, a robust timing concept is needed. The timing of the JCA publication, the currency of the literature search, additional data cuts and new studies may be decisive for whether the AMNOG dossier is based on the current evidence base. The Delta-Dossier should therefore not be understood as a downstream formality, but as the result of an early aligned evidence and market access strategy.
Explore EU HTA and AMNOG in the Delta-Dossier Map
The interface between EU HTA, JCA and AMNOG remains abstract as long as it is described only as a regulatory process. It becomes practically relevant where specific dossier content must be connected: Which information from the JCA dossier can be used for GermanyWhere are supplementary elements neededAnd where is it decided whether European evidence can carry weight in the AMNOG procedure
The interactive Delta-Dossier Map makes these transitions visible. It shows where JCA and AMNOG come together in the Delta-Dossier, from PICO scoping and appropriate comparator therapy to endpoints, evidence updates and timing. This makes it clear why the Delta-Dossier does not begin only at national submission, but must already be prepared during early evidence planning.
For pharmaceutical companies, the map provides orientation along the central assessment questions. It shows which European content may be applicable and where national requirements should be reviewed early. In this way, the regulatory interface between EU HTA and AMNOG becomes a concrete working framework for preparing the Delta-Dossier.
FAQ
What is EU HTA
EU HTA refers to European cooperation in the assessment of health technologies. In the pharmaceutical sector, the Joint Clinical Assessment is the central element. The aim is to assess clinical evidence jointly at European level and thereby better support national HTA procedures.
What does EU HTA mean for Germany
For Germany, EU HTA creates a new interface between European evidence assessment and the national AMNOG procedure. The European assessment provides a common clinical foundation. However, national benefit assessment, the assessment against the appropriate comparator therapy and the decision on added benefit remain anchored in the German procedure.
Does JCA replace the AMNOG procedure
No. The Joint Clinical Assessment does not replace the AMNOG procedure. It can provide evidence that is considered in the national procedure. The German assessment of added benefit, however, continues to follow national requirements, particularly with regard to G-BA, IQWiG, appropriate comparator therapy, patient-relevant endpoints and methodological standards.
What is the difference between a JCA dossier, an AMNOG dossier and a Delta-Dossier
The JCA dossier is designed for the joint European clinical assessment. The AMNOG dossier addresses the requirements of Germany’s early benefit assessment. The Delta-Dossier describes the content and evidence that becomes additionally relevant between these two levels: it translates European evidence into a form that can be used robustly in the German AMNOG procedure.
Why are references to the JCA dossier not always sufficient
References are sufficient only if the content of the JCA dossier actually covers the German assessment question. If populations, comparator therapies, endpoints, subgroups, analyses or evidence currency do not fit the German benefit assessment, additional national preparation is required.
What role do PICO scoping and appropriate comparator therapy play
PICO scoping determines early on which populations, interventions, comparators and outcomes are considered in the European procedure. For Germany, however, the decisive question is whether this structure fits the later AMNOG question and the appropriate comparator therapy. This is where important differences between EU HTA and national assessment may arise.
When does the Delta-Dossier become relevant
The Delta-Dossier does not become relevant only shortly before national submission. The decisive preparation begins already with PICO scoping, evidence planning, comparator therapy scenarios, endpoint selection, subgroup analyses and timing. The earlier these interfaces are considered, the better European evidence can be made usable for the German AMNOG procedure.